Kalp Transplantasyonunda İmmünoloji ve İmmünosupresyon

Ahmed T, Jain A. Heart Transplantation. 2023 May 22. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491503.

Sayegh MH, Carpenter CB. Transplantation 50 years later--progress, challenges, and promises. N Engl J Med. 2004;351(26):2761-6. doi: 10.1056/NEJMon043418.

Velleca A, Shullo MA, Dhital K, et al. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023;42(5):e1-e141. doi: 10.1016/j.healun.2022.10.015.

Tolou-Ghamari Z. Tacrolimus and cyclosporin pharmacotherapy, detection methods, cytochrome P450 enzymes after heart transplantation. Cardiovasc Hematol Agents Med Chem. 2024;22(2):106-113. doi: 10.2174/1871525721666230726150021.

Dwyer, Gaelen K., and Hēth R. Turnquist. "Untangling local pro-inflammatory, reparative, and regulatory damage-associated molecular-patterns (DAMPs) pathways to improve transplant outcomes." Frontiers in Immunology 12 (2021): 611910.

Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol. 2003;15(5):487-92. doi: 10.1016/s0952-7915(03)00100-6.

Firoz A, Geier S, Yanagida R, et al. Heart transplant human leukocyte antigen matching in the modern era. J Card Fail. 2024;30(2):362-372. doi: 10.1016/j.cardfail.2023.06.016

Starzl TE. History of clinical transplantation. World J Surg. 2000;24(7):759-82. doi: 10.1007/s002680010124.

Morelli AE, Thomson AW. Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction. Immunol Rev. 2003;196:125-46. doi: 10.1046/j.1600-065x.2003.00079.x.

Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: what is it all about? Am J Transplant. 2015;15(5):1148-54. doi: 10.1111/ajt.13192.

Thurman JM, Panzer SE, Le Quintrec M. The role of complement in antibody mediated transplant rejection. Mol Immunol. 2019;112:240-246. doi: 10.1016/j.molimm.2019.06.002.

García-Villegas R, Arni S. Hemoadsorption in organ preservation and transplantation: a narrative review. Life (Basel). 2023;14(1):65. doi: 10.3390/life14010065.

Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ıll patient during COVID-19 Pandemic: Expert Review and Recommendation. Blood Purif. 2021;50(1):17-27. doi: 10.1159/000508125.

Firoz A, Geier S, Yanagida R, et al. Heart transplant human leukocyte antigen matching in the modern era. J Card Fail. 2024;30(2):362-372. doi: 10.1016/j.cardfail.2023.06.016.

Ahmed T, Goyal A. Endomyocardial Biopsy. 2023 May 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491529.

Lee DH, Usmani A, Wu R, et al. Relationship between donor-derived cell-free DNA and tissue-based rejection-related transcripts in heart transplantation. J Heart Lung Transplant. 2024;43(7):1118-1125. doi: 10.1016/j.healun.2024.02.011.

Beck-da-Silva L, Bridi LH, Matte BS, Valle FH. Endomyocardial biopsy using rigid bioptome technique and the risk of tricuspid regurgitation after heart transplantation. Arq Bras Cardiol. 2024;121(10):e20240223. doi: 10.36660/abc.20240223.

Marrón-Liñares GM, Núñez L, Crespo-Leiro MG, et al. Polymorphisms in genes related to the complement system and antibody-mediated cardiac allograft rejection. J Heart Lung Transplant. 2018;37(4):477-485. doi: 10.1016/j.healun.2017.07.006.

Kim JV, Assadian S, Hollander Z, et al. Regulatory T cell biomarkers ıdentify patients at risk of developing acute cellular rejection in the first year following heart transplantation. Transplantation. 2023;107(8):1810-1819. doi: 10.1097/TP.0000000000004607.

Szymanska S, Grajkowska W, Sobieszczanska-Malek M, Zielinski T, Pyzlak M, Pronicki M. Prevalence of the Quilty effect in endomyocardial biopsy of patients after heart transplantation - from cellular rejection to antibody-mediated rejection? Pol J Pathol. 2016;67(3):216-220. doi: 10.5114/pjp.2016.63772.

Orang E, Sayyahfar S, Mahdavi M, Khanaliha K, Amiri M. Comparison of serologic status of Toxoplasma gondii infection in pre- and post-heart transplantation in a pediatric population: A preliminary study. Transpl Infect Dis. 2020 g;22(4):e13339. doi: 10.1111/tid.13339.

Sperry BW, Zein RE, Fendler TJ, et al. Stabilization of rapidly progressive cardiac allograft vasculopathy using mTOR inhibition after heart transplantation. J Card Fail. 2024;30(4):613-617. doi: 10.1016/j.cardfail.2023.10.483.

Usman AA, Taimen K, Wasielewski M, et al. Cardiac magnetic resonance T2 mapping in the monitoring and follow-up of acute cardiac transplant rejection: a pilot study. Circ Cardiovasc Imaging. 2012;5(6):782-90. doi: 10.1161/CIRCIMAGING.111.971101.

Randhawa MK, Sultana S, Stib MT, Nagpal P, Michel E, Hedgire S. Role of radiology in assessment of postoperative complications of heart transplantation. Radiol Clin North Am. 2024;62(3):453-471. doi: 10.1016/j.rcl.2023.12.002.

Habal M. Immunosuppression Management in Heart Transplantation. Methodist Debakey Cardiovasc J. 2025;21(3):40-50. doi: 10.14797/mdcvj.1596.

Kugathasan L, Rayner DG, Wang SM, et al. Induction therapy in heart transplantation: A systematic review and network meta-analysis for developing evidence-based recommendations. Clin Transplant. 2024;38(5):e15326. doi: 10.1111/ctr.15326. PMID: 38716786.

Söderlund C, Rådegran G. Immunosuppressive therapies after heart transplantation--The balance between under- and over-immunosuppression. Transplant Rev (Orlando). 2015;29(3):181-9. doi: 10.1016/j.trre.2015.02.005.

Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation. 2004;110(25):3858-65. doi: 10.1161/01.CIR.0000150332.42276.69.

Heegaard B, Nelson LM, Gustafsson F. Steroid withdrawal after heart transplantation in adults. Transpl Int. 2021;34(12):2469-2482. doi: 10.1111/tri.14142.

Dashti-Khavidaki S, Saidi R, Lu H. Current status of glucocorticoid usage in solid organ transplantation. World J Transplant. 2021 Nov 18;11(11):443-465. doi: 10.5500/wjt.v11.i11.443.

Bartz-Overman C, Li S, Puligandla B, Colaco N, Steiner J, Masha L. Two case reports of fulminant giant cell myocarditis treated with rabbit anti-thymocyte globulin. Eur Heart J Case Rep. 2024;8(4):ytae128. doi: 10.1093/ehjcr/ytae128.

Sivathasan C. Experience with cyclosporine in heart transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):346S-348S. doi: 10.1016/j.transproceed.2004.01.072.

Jorga A, Holt DW, Johnston A. Therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004;36(2 Suppl):396S-403S. doi: 10.1016/j.transproceed.2004.01.013.

Abd-Eldayem AM, Makram SM, Messiha BAS, Abd-Elhafeez HH, Abdel-Reheim MA. Cyclosporine-induced kidney damage was halted by sitagliptin and hesperidin via increasing Nrf2 and suppressing TNF-α, NF-κB, and Bax. Sci Rep. 2024;14(1):7434. doi: 10.1038/s41598-024-57300-x.

Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf. 1999;20(5):437-49. doi: 10.2165/00002018-199920050-00004. PMID: 10348094.

Sikma MA, van Maarseveen EM, van de Graaf EA, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. Am J Transplant. 2015;15(9):2301-13. doi: 10.1111/ajt.13309.

Guethoff S, Meiser BM, Groetzner J, et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. Transplantation. 2013;95(4):629-34. doi: 10.1097/TP.0b013e318277e378.

Tory R, Sachs-Barrable K, Goshko CB, Hill JS, Wasan KM. Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations. Transplantation. 2009;88(1):62-8. doi: 10.1097/TP.0b013e3181aa7d04.

Topilsky Y, Hasin T, Raichlin E, et al. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. Circulation. 2012;125(5):708-20. doi: 10.1161/CIRCULATIONAHA.111.040360.

Mabasa VH, Ensom MH. The role of therapeutic monitoring of everolimus in solid organ transplantation. Ther Drug Monit. 2005;27(5):666-76. doi: 10.1097/01.ftd.0000175911.70172.2e.

Arora S, Ueland T, Wennerblom B, et al. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. Transplantation. 2011;92(2):235-43. doi: 10.1097/TP.0b013e31822057f1.

Mohammadi O, Kassim TA. Azathioprine. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.

Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: Systematic Review and Meta-Analysis. Am J Transplant. 2016;16(12):3490-3503. doi: 10.1111/ajt.13863.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Mycophenolate.

Al-Khouja A, Chaudhri N, Velidedeoglu E, Belen O, Bi Y, Doddapaneni S, Chen J. Approval of mycophenolate mofetil for prophylaxis of organ rejection in pediatric recipients of heart or liver transplants: A Regulatory Perspective. Clin Pharmacol Ther. 2024;116(3):807-813. doi: 10.1002/cpt.3288.

Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387-94. doi: 10.1038/sj.leu.2404683.

Xia CQ, Chernatynskaya AV, Wasserfall CH, et al. Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice. BMC Immunol. 2012 ;13:70. doi: 10.1186/1471-2172-13-70.

Wilde MI, Goa KL. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs. 1996;51(5):865-94. doi: 10.2165/00003495-199651050-00010.

Rudzik KN, Rivosecchi RM, Palmer BA, et al. Basiliximab induction versus no induction in adult heart transplantation. Clin Transplant. 2023;37(5):e14937. doi: 10.1111/ctr.14937.

Chen TT, Greene MM, Everitt MD, Simpson KE. Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience. Pediatr Transplant. 2023 Mar;27(2):e14438. doi: 10.1111/petr.14438. Epub 2022 Nov 17. PMID: 36397270.